In fact, in 2021, the guidelines of the National Comprehensive Cancer Network removed anthracycline-based therapy from the list of recommended regimens for the treatment of early-stage HER2-positive breast cancer [10]. This evidence concerns the gene ERBB2 and breast carcinoma.